Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.20 -1.29% 91.80 91.40 92.40 93.20 90.00 93.20 1,341,222 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -29.4 -36.8 - 121

4d Pharma Share Discussion Threads

Showing 12576 to 12598 of 15625 messages
Chat Pages: Latest  505  504  503  502  501  500  499  498  497  496  495  494  Older
DateSubjectAuthorDiscuss
23/10/2020
07:57
This time next year Stig we'll be ..............
magli
23/10/2020
07:57
Topped up three times today, general trading, SIPP and isa. Got in fine all three buys, smallish amounts. Fell asleep last night reading stigs posts...in a good way.. where have the shorters gone today hmmmm? Happy days
ovenman
23/10/2020
07:56
I'm pretty sure the share price will get to £2 before it gets back to £1, if it ever does again .
divmad
23/10/2020
07:54
No its not u plick
justtrying1
23/10/2020
07:54
Careful can see this dropping like a stone
justtrying1
23/10/2020
07:52
£2 is next stop guys
deanmatlazin
23/10/2020
07:45
I wish I could, totally skinned, unless my OpGen is doing something soon, which is waiting for a FDA approval for a diagnostic tool, I have nothing left to invest. But I would, for sure
thresholdbypass
23/10/2020
07:43
Yesterday's news was completely left field but stroke of genius imo. Resolved any short term funding issues whilst rapidly bringing forward Nasdaq listing. In one fell swoop they have resolved all the near term financial challenges and we can now let the science and the clinical trials progress unhindered. The presentation of 3 posters following yesterday's interview with CEO sets us up for explosive growth phase into Nasdaq listing.
blueblood
23/10/2020
07:41
To be honest, with all the information we now know, I can't see why anyone WOULDN'T want to be filling their boots with DDDD stock at these low levels. I know I am. Have bought more today.
someuwin
23/10/2020
07:40
This is all blocked up, like yesterday, it is a huge pile of money trying to squeze through a tiny opening. Once that pile becomes too large, the opening will burst, i.e. share price will rocket
thresholdbypass
23/10/2020
07:35
Cannot buy even about 1000 quid of shares
tomv33
23/10/2020
07:33
I have been doing random £5k buys and sells ( dummy ) and on line can sell nearly every time, goes NT on most buys. MM seems to be short on shares this morning. Makes a pleasant change if that is the case.
showmethemoneyhoney01
23/10/2020
07:31
Would like us back above £1.50 next week. £1.30 close today would be good start!
blueblood
23/10/2020
07:29
Once this is listing in Nasdaq...this will rocket upward.
deanmatlazin
23/10/2020
07:26
Difficult to buy any quantity.
someuwin
23/10/2020
07:26
10x - Seres level 100x - 10x bigger and better than Seres 1000x - 'more importantly we'll be presenting monotherapy data' 😂😎
the stigologist
23/10/2020
07:26
Crazy we are still only priced marginally above the funding stike price level! So much uncertainty removed and were now Nasdaq listed, where Pharma Co valuations are sky high, it doesn't take genius to realise that once the US investor community get their heads around 4D's market leading position and partnerships the will be a stampede for Shares! I've been buying all I can afford yesterday and this morning it's rare you get this kind of gilts edged opportunity gifted on a plate
trotterstrading
23/10/2020
07:21
I think it is sometimes worth pausing as well and thinking about what a vaccine is. Does a tablet that you take once a week which materially reduces your chance of suffering from a disease count?And the neuro-degenerative work is clearly very exciting. So many irons in the fire, any of which would be utterly transformative
mad foetus
23/10/2020
07:18
When is the nasdaq listing?
tomv33
23/10/2020
07:12
Looks like £2 is the next stop before listing in Nasdaq.
deanmatlazin
23/10/2020
07:08
So, The Stigologist, I hope it gets to 200 pounds then
thresholdbypass
23/10/2020
07:06
mad foetus Some good points and it may well be that as a monotherapy, the ideal setting for live biotherapeutics is in very early stage cancers, as a neoadjuvant and then adjuvant therapy (before and after the tumour is completely surgically removed). In those settings the route to approval would be in large randomised studies where efficacy is proven by differences in both progression free and overall survival between the treatment and control arms. It's interesting to look at the development history of the PD-1s - they started with late stage, inoperable cancers in patients who had failed all other treatments. Then they moved to the same setting but as a first line treatment and they have gradually moved to earlier and earlier settings. We're now at the stage where Merck have applied for FDA approval in the eariest, neoadjuvant setting for breast cancer. However, they have only applied for use in combination with chemo and for patients whose tumours express a certain level of PD-L1. The point I'm making is that due to the cost and toxicity, it's hard to see how any of the PD-1s can secure FDA approval in a setting any earlier than the above but there are huge numbers of patients who have a localised tumour which is treated by simple excision and it would be fantastic if live biotherapeutics could be a safe and easy way of reducing the numbers who go on to progress.
bermudashorts
23/10/2020
06:51
MF, As per the interview on Monday Keytruda has only a 30% success rate, now consider MRx 0518 managed to have a success rate of 42% with Keytruda on patients that had failed to respond to Keytruda and other treatments and were very sick, now give patients Keytruda and MRx 0518 earlier as primary treatments, that success rate could increase dramatically. Maybe we will find out more in the upcoming conference, and by the excitement coming from 4d / Duncan, groundbreaking data was mentioned in the latest presentation. You just have to use your imagination where 4D could be going. GLA
s_murray
Chat Pages: Latest  505  504  503  502  501  500  499  498  497  496  495  494  Older
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201202 17:13:42